Detalhe da pesquisa
1.
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Blood
; 139(8): 1135-1146, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543383
2.
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
Oncologist
; 28(10): 901-910, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120291
3.
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
Blood
; 138(19): 1885-1895, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075412
4.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
5.
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Cancer
; 127(6): 905-913, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231879
6.
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Cancer
; 127(7): 1039-1048, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259056
7.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Blood
; 133(14): 1548-1559, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658992
8.
Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients.
Biol Blood Marrow Transplant
; 26(8): 1505-1510, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32439476
9.
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Blood
; 132(11): 1125-1133, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045838
10.
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Blood
; 131(4): 387-396, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196412
11.
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 25(9): 1720-1729, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31039409
12.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant
; 25(11): 2113-2123, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446198
13.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Cancer
; 125(14): 2474-2487, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30920645
14.
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
N Engl J Med
; 375(8): 740-53, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27292104
15.
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Am J Hematol
; 94(4): 408-416, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30623490
16.
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Cancer
; 124(8): 1722-1732, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381191
17.
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Br J Haematol
; 191(3): e77-e81, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32805058
18.
Genomics of therapy-related myeloid neoplasms.
Haematologica
; 105(3): e98-e101, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31413096
19.
Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Future Oncol
; 11(12): 1729-39, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26075441
20.
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Br J Haematol
; 165(4): 504-9, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24579885